Replimune Group, Inc.
NASDAQREPL cost to borrow surges to 1.2% from 0.53% in one week, up 128% — a rare spike for the Nasdaq-listed biotech as short covering accelerates.
Snapshot as of 10 Aug 2026
Options traders have turned sharply bearish on REPL just as short sellers begin covering. The divergence is the standout story on Replimune Group right now. The put-call ratio hit 0.71 on July 15. That is 2.47 standard…
REPL heads into its June 4 earnings with one of the most combustible positioning setups in small-cap biotech: a heavily shorted stock that has tripled in a month. The short-side squeeze pressure is genuine. Short…
Replimune Group enters its May 15 earnings report in one of the most electrically charged setups in the biotech space right now: a 43% weekly surge, a third of the float still sold short, and call buyers running the…
Replimune Group heads into its May 15 earnings with nearly a quarter of its free float sold short — a position that has been building quietly since a devastating regulatory setback in April. Short interest commands the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for REPL — free to start on ORTEX.
Sign up for free →Open REPL on ORTEX